Happened to notice this corporate announcement this morning (I’m not invested or involved in this company and it’s the first time I’ve seen anything from them):-
Genflow Biosciences Plc
Genflow Advances World’s First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (“Genflow” or “the Company”), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.
The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026.
The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment.
Study objectives are to:
- Confirm feasibility of GF-1004 administration in the target population.
- Validate safety and efficacy at the proposed administered dose.
- Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including:
o Reduced biological age (GRIM methylation clock)
o Increased muscle strength and mass
o Enhanced mitochondrial function
o Improved coat quality
o Better overall health metrics
Translational Potential
Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics.
Dr. Eric Leire, CEO of Genflow, commented: “Now that all dogs have received the treatment without any adverse events, we’ve taken an important step in confirming the treatment’s safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans.”
